Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Breast 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1

Conditions

Triple Negative Breast Neoplasms 2Neoplasm Metastasis 1Breast Neoplasms 1

Interventions

Trastuzumab 379Paclitaxel 369Cyclophosphamide 338Docetaxel 314Capecitabine 198Doxorubicin 196Letrozole 184Tamoxifen 154Carboplatin 153Fulvestrant 136Bevacizumab 129Anastrozole 120exemestane 119Lapatinib 117Epirubicin 116Gemcitabine 112Radiotherapy 107palbociclib 94Exercise 87Fluorouracil 83Vinorelbine 82Surveys and Questionnaires 81pertuzumab 77Albumin-Bound Paclitaxel 76Filgrastim 71130-nm albumin-bound paclitaxel 64pembrolizumab 63Everolimus 59Cisplatin 59eribulin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Glucose × Breast × Clear all
NCT04799249 2024-08-01

PRESERVE 2

G1 Therapeutics, Inc.

Phase 3 Completed
194 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03457779 2021-10-08

Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast Cancer

Baylor Research Institute

Phase NA Completed
16 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡